Sofwave Medical Ltd
TASE:SOFW
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 196
2 021
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sofwave Medical Ltd
Cash & Cash Equivalents
Sofwave Medical Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Cash & Cash Equivalents
$24.4m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Cash & Cash Equivalents
$56.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Brainsway Ltd
TASE:BWAY
|
Cash & Cash Equivalents
$46m
|
CAGR 3-Years
39%
|
CAGR 5-Years
39%
|
CAGR 10-Years
16%
|
|
|
Inmode Ltd
NASDAQ:INMD
|
Cash & Cash Equivalents
$403.4m
|
CAGR 3-Years
49%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Sisram Medical Ltd
HKEX:1696
|
Cash & Cash Equivalents
$70.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Cash & Cash Equivalents
$15.6m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sofwave Medical Ltd
Glance View
Sofwave Medical Ltd. engages in development, production, marketing, maintenance, and distribution of medical technology for firming and rejuvenating facial and neck skin. The firm operates itself and through its subsidiaries in the field of development, production, marketing, support and distribution of medical technology Sofwave that delivers Synchronous Ultrasound Parallel Beam SUPERB technology for skin tightening and rejuvenation treatments for the face and neck, which provides a non-invasive solution for skin rejuvenation and tightening, in a safe and clinically effective manner. In addition, the group provides services technical and clinical support for the product it provides. The firm has subsidiary in United States -Sofwave Medical Inc.
See Also
What is Sofwave Medical Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
24.4m
USD
Based on the financial report for Dec 31, 2023, Sofwave Medical Ltd's Cash & Cash Equivalents amounts to 24.4m USD.
What is Sofwave Medical Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
110%
Over the last year, the Cash & Cash Equivalents growth was -24%. The average annual Cash & Cash Equivalents growth rates for Sofwave Medical Ltd have been 110% over the past three years .
You don't have any saved screeners yet
